PCOS Has a New Name: What 'Polyendocrine Metabolic Ovarian Syndrome' (PMOS) Means for Diagnosis and Naturopathic Care

This article is for educational purposes intended for healthcare practitioners and informed readers. It does not constitute medical advice.

Why This Matters for Naturopathic Practice

In May 2026, a global consensus process led by Helena Teede and colleagues, writing for the Global Name Change Consortium, published a paper in The Lancet proposing that polycystic ovary syndrome (PCOS) be renamed polyendocrine metabolic ovarian syndrome (PMOS). The paper, "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process," drew on more than 14,000 survey responses from patients and health professionals worldwide, two rounds of Delphi surveys, and nominal group workshops, and was endorsed by dozens of professional and patient organisations including the Androgen Excess and PCOS Society and Verity. Eighty-six percent of surveyed patients and 71% of health professionals supported the change.

This is squarely relevant to naturopathic and functional practitioners because PCOS is one of the most common conditions seen in integrative women's health practice, and because the rationale for the rename bears directly on two things practitioners do every week: how the diagnosis is explained to a newly diagnosed patient, and whether ultrasound is needed to make or confirm it. This article covers what actually changed, what did not, and a companion study published alongside the renaming effort that directly affects how "cysts" should be discussed with patients. Our existing PCOS naturopathic protocol and PCOS multimodal therapy trial evidence review cover the treatment evidence in depth; this article does not revisit that evidence, since the rename does not change it.

What Actually Changed: A Name, Not a Diagnosis

It is worth being precise about the scope of this change, because the amount of media coverage it has generated could easily be mistaken for a clinical practice overhaul. It is not one. Secondary commentary on the consensus process, including coverage in the American Journal of Obstetrics & Gynecology, states plainly that the rename leaves the condition's underlying biology and diagnostic criteria unchanged. The Rotterdam criteria, the three-part framework (oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone, with any two of three sufficient for diagnosis) that has underpinned PCOS diagnosis internationally since 2003, is not being revised by this paper. The existing International Evidence-based Guideline for the Assessment and Management of PCOS, most recently updated in 2023, continues to apply, and the Lancet authors note that the next full evidence update to that guideline, expected in 2028, is what will formally incorporate the new terminology into its recommendations.

What the consensus process targeted was narrower and, the authors argue, more consequential than it might first appear: the word "cysts." The rationale, echoed across multiple post-publication commentaries, is that the name "polycystic ovary syndrome" misleadingly centres the condition on an ovarian ultrasound finding that is not actually a disease-defining pathology, at the expense of the metabolic and broader endocrine features that drive most of the condition's clinical burden and that are far more relevant to how it should be managed.

The Companion Finding: PCOS Is Not a "Cyst Disease"

The renaming effort was accompanied by a separate, directly relevant study: Piltonen, Kuusiniemi, and Teede, on behalf of the WENDY Research Group, "Ovarian Cysts in Polycystic Ovary Syndrome," published in JAMA Internal Medicine in May 2026. This was a cross-sectional analysis drawn from the prospective, population-based Women's Health Study (WENDY) cohort in Finland: 1,904 women aged 33 to 37 were examined by gynaecological ultrasound at two university clinics, and after excluding hormonal contraceptive users, 1,235 remained for analysis (223 with PCOS by Rotterdam criteria, 1,012 without).

The key finding is that women with PCOS showed no significantly higher prevalence of benign or pathological ovarian cysts, specifically, simple cysts, paraovarian cysts, haemorrhagic cysts, endometriomas, or dermoid cysts, compared with women without PCOS. What the PCOS group did show far more of was a high antral follicle count: an odds ratio of 11.83 (95% CI 8.44 to 16.58) for having 20 or more antral follicles (2 to 9 mm) in at least one ovary, and an odds ratio of 12.18 (95% CI 8.29 to 17.89) for ovarian volume of 10 mL or more. Corpus luteum prevalence was actually lower in the PCOS group (odds ratio 0.65, 95% CI 0.47 to 0.90), consistent with the anovulation that characterises the condition.

In other words, the "polycystic" appearance on ultrasound reflects an excess of small, growth-arrested antral follicles, which is a real and diagnostically useful finding, not an excess of actual cysts in the pathological sense that the word "cyst" implies to most patients and many clinicians. The authors frame this distinction as central to the case for renaming: the follicle-count finding is genuine and diagnostically relevant, but it is not evidence of ovarian pathology requiring surgical or gynaecological-oncology concern, which is the association the word "cyst" tends to trigger. Note that the JAMA Internal Medicine article received a correction to its Results section on June 15, 2026; the odds ratios above are corroborated across two independent secondary summaries of the corrected findings, and should be treated as the current published figures, but readers consulting the primary article should confirm against the corrected version.

What This Means for the Ultrasound Conversation

A specific, practical implication raised in post-publication clinical commentary is about when ultrasound is actually needed. This is not a new rule introduced by the renaming, it restates existing international guideline practice, but the renaming has brought new attention to it: when a patient already meets two of the three Rotterdam criteria on history, examination, and biochemistry alone (for example, documented irregular cycles plus clinical or biochemical hyperandrogenism), an ultrasound is not required to establish the diagnosis. The existing international guideline also advises against using ultrasound for diagnosis in adolescents, given the high rate of multifollicular ovaries as a normal finding in that age group. For naturopathic practitioners who refer patients for pelvic ultrasound as a default step in PCOS workup, this is a reasonable point to revisit: an unnecessary scan does not just add cost and a wait, it also reintroduces the "cyst" framing that this entire body of work is trying to move away from, and can leave a patient more anxious about her ovaries than the underlying biology warrants.

What Did Not Change: The Treatment Evidence

It bears repeating because it is easy to lose in the volume of coverage: nothing about this renaming changes what is or is not evidence-supported for managing the metabolic, reproductive, and dermatological features of PCOS/PMOS. Lifestyle intervention remains first-line per the existing international guideline, and the inositol, metformin, and combined-diet trial evidence covered in our PCOS multimodal therapy trial evidence review stands exactly as it did before May 2026. The renaming paper itself is a nomenclature and knowledge-translation intervention, assessed through survey methodology and stakeholder consensus, not a clinical trial, and should not be cited as new treatment evidence. Clinicians should also expect a multi-year transition: Teede has been quoted in post-publication coverage estimating roughly three years before the new name is in widespread clinical and public use, with full guideline incorporation not expected until 2028. During that window, patients will encounter both names interchangeably across clinical letters, lab requisitions, and patient materials, and it is reasonable for practitioners to use both names together in documentation and conversation for some time rather than assuming PMOS is already universally understood.

A Caveat on the Consensus Itself

The renaming has not been without pushback. Lancet-published commentary responding to the consensus paper has argued that "polyendocrine metabolic ovarian syndrome" is itself not a fully precise biological label, and that the real value of the exercise may lie less in the specific replacement name than in the broader shift away from a cysts-centred framing. That is a fair point to hold alongside the consensus data: a name arrived at by structured stakeholder process with strong majority support is not the same thing as a name validated against the condition's actual heterogeneous biology, which remains an active area of research (the same group has previously proposed subtyping PCOS by reproductive, metabolic, and mixed phenotypes). Practitioners should treat "PMOS" as the current, broadly endorsed terminology rather than as a settled, final scientific descriptor.

Practical Takeaways for Naturopathic Practice

• Expect patients to arrive having seen "PMOS" in the media, possibly confused about whether it is a different or new condition. It is not; it is the same diagnosis, same criteria, under evolving terminology.
• Do not order or recommend pelvic ultrasound as a default diagnostic step when two Rotterdam criteria are already met on history and biochemistry; this was already the guideline position and the renaming effort has simply drawn fresh attention to it.
• When discussing ultrasound findings with patients, use "follicles," not "cysts," and explain explicitly that the JAMA Internal Medicine companion study found no increase in pathological ovarian cysts in PCOS/PMOS, so a scan showing a polycystic-appearing ovary is not a sign of ovarian disease requiring surgical concern.
• Continue to apply the existing evidence base for lifestyle, inositol, and metabolic management unchanged; this renaming is a communication and diagnostic-framing update, not a treatment update.
• Use both names in parallel in clinical notes and patient materials during the multi-year transition period, since the 2028 guideline update is the point at which "PMOS" is expected to become the sole standard term.

When to Refer or Escalate

The renaming does not change existing referral thresholds for PCOS/PMOS. Significant hirsutism, rapid-onset virilisation, or markedly elevated androgens still warrant endocrinology referral to exclude androgen-secreting tumours or non-classic congenital adrenal hyperplasia. Fertility concerns, persistent amenorrhoea, or endometrial protection questions in the context of chronic anovulation should involve a gynaecologist or reproductive endocrinologist. Any adnexal mass identified incidentally on ultrasound still requires standard gynaecological assessment; the JAMA Internal Medicine findings concern population-level cyst prevalence, not individual mass characterisation.

Clinical Summary

A 2026 global consensus process, published in The Lancet by Teede and colleagues on behalf of the Global Name Change Consortium, has renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS), based on more than 14,000 survey responses and broad professional and patient endorsement. The rename does not alter the Rotterdam diagnostic criteria or the existing treatment evidence base, and full guideline incorporation is not expected until 2028. A companion study in JAMA Internal Medicine (Piltonen, Kuusiniemi, Teede, and the WENDY Research Group) found that women with PCOS/PMOS do not have a higher prevalence of pathological ovarian cysts compared with women without the condition, despite showing far higher antral follicle counts and ovarian volume on ultrasound, supporting the case that "cysts" was always a misleading description. For naturopathic practice, the practical implications are in language and diagnostic workflow rather than treatment: avoid unnecessary ultrasound once Rotterdam criteria are met biochemically and clinically, correct the "cyst" framing explicitly with patients, and continue applying the existing lifestyle and supplement evidence base without modification.

References

• Teede HJ, Khomami MB, Morman R, Laven JSE, Joham AE, Costello MF, Patil M, Rees DA, Berry L, Cree MG, Zhao H, Norman RJ, Dokras A, Piltonen T; Global Name Change Consortium. "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." The Lancet. 2026;407(10545):2329-2339. DOI: 10.1016/S0140-6736(26)00717-8. PMID: 42119588.
• Piltonen TT, Kuusiniemi E, Teede H; WENDY Research Group study group. "Ovarian Cysts in Polycystic Ovary Syndrome." JAMA Internal Medicine. Published online May 11, 2026. DOI: 10.1001/jamainternmed.2026.1370.
• Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE; International PCOS Network. "Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." Human Reproduction. 2023;38(9):1655-1679. DOI: 10.1093/humrep/dead156.
• Endocrine Society. "PCOS Name Change." Press release, 2026. endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change.

This article is intended for educational purposes and professional practice reference. It does not constitute individual medical advice. Any new or changing gynaecological symptoms, or an incidental ovarian mass found on imaging, should be assessed by a qualified healthcare provider.